The new guidance for migraine prevention encouraged which therapies as first-line?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

The new guidance for migraine prevention encouraged which therapies as first-line?

Directly targeting the CGRP pathway is favored as a first-line approach for migraine prevention because it tackles a key driver of attacks. CGRP is a neuropeptide released during migraines that promotes pain signaling and vascular changes. Blocking CGRP or its receptor with monoclonal antibodies reduces how often migraines occur, with strong evidence from randomized trials showing meaningful reductions in monthly migraine days and good responder rates. These therapies tend to have a favorable safety and tolerability profile compared with traditional preventive drugs like beta-blockers, anticonvulsants, or antidepressants, which often cause systemic side effects such as fatigue, weight changes, cognitive effects, or blood pressure issues. They also offer convenient dosing (monthly or quarterly injections) that can improve adherence. Because of the combination of strong efficacy, better tolerability, and easier administration, newer CGRP-targeting therapies are encouraged as a first-line option in updated migraine prevention guidelines.

Directly targeting the CGRP pathway is favored as a first-line approach for migraine prevention because it tackles a key driver of attacks. CGRP is a neuropeptide released during migraines that promotes pain signaling and vascular changes. Blocking CGRP or its receptor with monoclonal antibodies reduces how often migraines occur, with strong evidence from randomized trials showing meaningful reductions in monthly migraine days and good responder rates.

These therapies tend to have a favorable safety and tolerability profile compared with traditional preventive drugs like beta-blockers, anticonvulsants, or antidepressants, which often cause systemic side effects such as fatigue, weight changes, cognitive effects, or blood pressure issues. They also offer convenient dosing (monthly or quarterly injections) that can improve adherence.

Because of the combination of strong efficacy, better tolerability, and easier administration, newer CGRP-targeting therapies are encouraged as a first-line option in updated migraine prevention guidelines.

More practice questions